Chelation therapy and bone metabolism markers in thalassemia major

Loredana Pratelli, Elisabetta Verri, Monica Fortini, Stefano Marconi, Carola Zolezzi, Pier Maria Fornasari, Maria Rita Gamberini, Vincenzo De Sanctis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of our study was to investigate the effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1) therapy on bone metabolism markers in patients with thalassemia major. We studied 17 patients with thalassemia receiving long-term treatment with desferrioxamine, 20 patients receiving long-term treatment with deferiprone, and 15 healthy age-matched controls. The following investigations were performed: a) intact parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-vitamin D [1,25(OH) 2D] as endocrine parameters; b) alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), osteocalcin (OC); c) bone resorption biochemical markers in serum and urine pyridinium crosslinks: hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP); d) serum levels of cytokines and growth factors: transforming growth factor-β1 (TGFβ1), insulin-like growth factor-I (IGF-I), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα); e) serum levels of IGF binding protein-3 (IGFBP-3). No significant differences among all studied variables were found in patients with thalassemia treated with desferrioxamine or deferiprone. In contrast, significant differences were found between patients with thalassemia and the control group: intact PTH was significantly lower in patients with thalassemia than in the controls (p

Original languageEnglish
Pages (from-to)1335-1342
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume19
Issue number11
Publication statusPublished - Nov 2006

Fingerprint

Chelation Therapy
beta-Thalassemia
Thalassemia
Bone and Bones
Deferoxamine
Parathyroid Hormone
Alkaline Phosphatase
Serum
Insulin-Like Growth Factor Binding Protein 3
Osteocalcin
Transforming Growth Factors
Bone Resorption
Insulin-Like Growth Factor I
Interleukin-1
Vitamin D
Interleukin-6
Intercellular Signaling Peptides and Proteins
Therapeutics
Tumor Necrosis Factor-alpha
Biomarkers

Keywords

  • Bone metabolism
  • Chelation therapy
  • Osteoporosis
  • Thalassemia

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Pratelli, L., Verri, E., Fortini, M., Marconi, S., Zolezzi, C., Fornasari, P. M., ... De Sanctis, V. (2006). Chelation therapy and bone metabolism markers in thalassemia major. Journal of Pediatric Endocrinology and Metabolism, 19(11), 1335-1342.

Chelation therapy and bone metabolism markers in thalassemia major. / Pratelli, Loredana; Verri, Elisabetta; Fortini, Monica; Marconi, Stefano; Zolezzi, Carola; Fornasari, Pier Maria; Gamberini, Maria Rita; De Sanctis, Vincenzo.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 19, No. 11, 11.2006, p. 1335-1342.

Research output: Contribution to journalArticle

Pratelli, L, Verri, E, Fortini, M, Marconi, S, Zolezzi, C, Fornasari, PM, Gamberini, MR & De Sanctis, V 2006, 'Chelation therapy and bone metabolism markers in thalassemia major', Journal of Pediatric Endocrinology and Metabolism, vol. 19, no. 11, pp. 1335-1342.
Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM et al. Chelation therapy and bone metabolism markers in thalassemia major. Journal of Pediatric Endocrinology and Metabolism. 2006 Nov;19(11):1335-1342.
Pratelli, Loredana ; Verri, Elisabetta ; Fortini, Monica ; Marconi, Stefano ; Zolezzi, Carola ; Fornasari, Pier Maria ; Gamberini, Maria Rita ; De Sanctis, Vincenzo. / Chelation therapy and bone metabolism markers in thalassemia major. In: Journal of Pediatric Endocrinology and Metabolism. 2006 ; Vol. 19, No. 11. pp. 1335-1342.
@article{14f36cbd7db54c82aa017dcfa4b26db2,
title = "Chelation therapy and bone metabolism markers in thalassemia major",
abstract = "The aim of our study was to investigate the effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1) therapy on bone metabolism markers in patients with thalassemia major. We studied 17 patients with thalassemia receiving long-term treatment with desferrioxamine, 20 patients receiving long-term treatment with deferiprone, and 15 healthy age-matched controls. The following investigations were performed: a) intact parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-vitamin D [1,25(OH) 2D] as endocrine parameters; b) alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), osteocalcin (OC); c) bone resorption biochemical markers in serum and urine pyridinium crosslinks: hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP); d) serum levels of cytokines and growth factors: transforming growth factor-β1 (TGFβ1), insulin-like growth factor-I (IGF-I), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα); e) serum levels of IGF binding protein-3 (IGFBP-3). No significant differences among all studied variables were found in patients with thalassemia treated with desferrioxamine or deferiprone. In contrast, significant differences were found between patients with thalassemia and the control group: intact PTH was significantly lower in patients with thalassemia than in the controls (p",
keywords = "Bone metabolism, Chelation therapy, Osteoporosis, Thalassemia",
author = "Loredana Pratelli and Elisabetta Verri and Monica Fortini and Stefano Marconi and Carola Zolezzi and Fornasari, {Pier Maria} and Gamberini, {Maria Rita} and {De Sanctis}, Vincenzo",
year = "2006",
month = "11",
language = "English",
volume = "19",
pages = "1335--1342",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "11",

}

TY - JOUR

T1 - Chelation therapy and bone metabolism markers in thalassemia major

AU - Pratelli, Loredana

AU - Verri, Elisabetta

AU - Fortini, Monica

AU - Marconi, Stefano

AU - Zolezzi, Carola

AU - Fornasari, Pier Maria

AU - Gamberini, Maria Rita

AU - De Sanctis, Vincenzo

PY - 2006/11

Y1 - 2006/11

N2 - The aim of our study was to investigate the effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1) therapy on bone metabolism markers in patients with thalassemia major. We studied 17 patients with thalassemia receiving long-term treatment with desferrioxamine, 20 patients receiving long-term treatment with deferiprone, and 15 healthy age-matched controls. The following investigations were performed: a) intact parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-vitamin D [1,25(OH) 2D] as endocrine parameters; b) alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), osteocalcin (OC); c) bone resorption biochemical markers in serum and urine pyridinium crosslinks: hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP); d) serum levels of cytokines and growth factors: transforming growth factor-β1 (TGFβ1), insulin-like growth factor-I (IGF-I), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα); e) serum levels of IGF binding protein-3 (IGFBP-3). No significant differences among all studied variables were found in patients with thalassemia treated with desferrioxamine or deferiprone. In contrast, significant differences were found between patients with thalassemia and the control group: intact PTH was significantly lower in patients with thalassemia than in the controls (p

AB - The aim of our study was to investigate the effects of subcutaneous desferrioxamine (DFX) and oral deferiprone (L1) therapy on bone metabolism markers in patients with thalassemia major. We studied 17 patients with thalassemia receiving long-term treatment with desferrioxamine, 20 patients receiving long-term treatment with deferiprone, and 15 healthy age-matched controls. The following investigations were performed: a) intact parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-vitamin D [1,25(OH) 2D] as endocrine parameters; b) alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), osteocalcin (OC); c) bone resorption biochemical markers in serum and urine pyridinium crosslinks: hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP); d) serum levels of cytokines and growth factors: transforming growth factor-β1 (TGFβ1), insulin-like growth factor-I (IGF-I), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNFα); e) serum levels of IGF binding protein-3 (IGFBP-3). No significant differences among all studied variables were found in patients with thalassemia treated with desferrioxamine or deferiprone. In contrast, significant differences were found between patients with thalassemia and the control group: intact PTH was significantly lower in patients with thalassemia than in the controls (p

KW - Bone metabolism

KW - Chelation therapy

KW - Osteoporosis

KW - Thalassemia

UR - http://www.scopus.com/inward/record.url?scp=33845711446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845711446&partnerID=8YFLogxK

M3 - Article

C2 - 17220062

AN - SCOPUS:33845711446

VL - 19

SP - 1335

EP - 1342

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 11

ER -